YPEL2 regulates the efficacy of BRD4-EZH2 dual targeting in EZH2Y641mut germinal center-derived lymphoma
Por:
Chamorro-Jorganes, A, Profitós-Pelejà, N, Recasens-Zorzo, C, Valero, J, Reyes-Garau, D, Magnano, L, Butler, R, Postigo, A, Pérez-Galán, P, Ribeiro, ML and Roué, G
Publicada:
1 mar 2025
Ahead of Print:
1 feb 2025
Resumen:
A significant proportion of diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) cases harbor a gain-of-function, heterozygous somatic mutation of the methyltransferase gene EZH2. While this factor is known to cooperate with the proto-oncogene MYC during malignant B cell development, the effect of interfering with both factors remains underexplored. Here we undertook the simultaneous evaluation of two epigenetic drugs targeting EZH2 methyltransferase activity and BRD4-mediated control of MYC transcription, CPI169 and CPI203, using preclinical models of DLBCL and FL with distinct EZH2 mutational status. We observed a specific and synergistic antiproliferative effect of these compounds in EZH2-mutated cells and mouse xenograft models, that was related to the abrogation of MYC transcriptional program and to tumor cell proliferation blockade at the G1 cell cycle phase. Gene expression profile, exploratory data analysis, and siRNA screening identified the PI3K/ AKT-regulated gene and mitosis regulator, YPEL2, as a crucial factor involved in the efficacy of MYC/EZH2 dual targeting both in vitro and in vivo. Altogether, our results provide first pre-clinical evidence that simultaneous targeting of MYC and EZH2 is a safe and efficient approach that can be monitored by specific biomarkers, in aggressive lymphoid tumors of germinal center origin.
Filiaciones:
Chamorro-Jorganes, A:
Inst Invest Biomed August Pi i Sunyer IDIBAPS, Div Hematooncol, Barcelona, Spain
:
Inst Invest Biomed August Pi i Sunyer IDIBAPS, Div Hematooncol, Barcelona, Spain
Josep Carreras Leukaemia Res Inst IJC, Lymphoma Translat Grp, Badalona, Spain
Recasens-Zorzo, C:
Inst Invest Biomed August Pi i Sunyer IDIBAPS, Div Hematooncol, Barcelona, Spain
Valero, J:
Inst Invest Biomed August Pi i Sunyer IDIBAPS, Div Hematooncol, Barcelona, Spain
Ctr Invest Biomed Red Oncol CIBERONC, Madrid, Spain
Reyes-Garau, D:
Josep Carreras Leukaemia Res Inst IJC, Lymphoma Translat Grp, Badalona, Spain
Magnano, L:
Inst Invest Biomed August Pi i Sunyer IDIBAPS, Div Hematooncol, Barcelona, Spain
Butler, R:
Butler Sci, Barcelona, Spain
Postigo, A:
ICREA, Grp Gene Regulat Stem Cells & Cell Plast, IDIBAPS, Barcelona, Spain
Pérez-Galán, P:
Inst Invest Biomed August Pi i Sunyer IDIBAPS, Div Hematooncol, Barcelona, Spain
Ctr Invest Biomed Red Oncol CIBERONC, Madrid, Spain
Ribeiro, ML:
Josep Carreras Leukaemia Res Inst IJC, Lymphoma Translat Grp, Badalona, Spain
Sao Francisco Univ, Med Sch, Lab Immunopharmacol & Mol Biol, Braganca Paulista, SP, Brazil
:
Josep Carreras Leukaemia Res Inst IJC, Lymphoma Translat Grp, Badalona, Spain
Green Submitted, gold
|